logo
episode-header-image
May 2023
14m 1s

Reasons for Failure and Relapse and Mech...

European Hematology Association
About this episode
tail spinning
Up next
Aug 21
Outpatient CAR T in Europe: Lessons from Barcelona
In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantatio ... Show More
27m 3s
Aug 18
Smarter CARs: Using AI to Improve Chimeric Antigen Receptor Design
Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, partic ... Show More
17m 42s
Aug 17
What is Real-World Evidence Revealing About CAR T Therapy?
In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, inc ... Show More
18m 39s
Recommended Episodes
May 2023
73: Fast & Feverish: Intro to CAR-T & Early ID Complications
In Part 1 of this pair of episodes, Drs. Rita Dib and Joseph Sassine provide a background of CAR-T cell therapy (chimeric antigen receptor T cells) and steer you through the complications that might contribute to fever early after CAR-T.Episodes | Consult Notes | Subscribe | Twit ... Show More
38m 45s
May 2023
74: 2 Fast 2 Feverish: Late ID Complications of CAR-T therapy
In Part 2 of this pair of episodes, Drs. Rita Dib and Joseph Sassine zoom through the late infectious complications of CAR-T cell therapy.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com 
46m 18s
Sep 2025
Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
<p class="" data-rte-preserve-empty="true" style="white-space:pre-wrap;"><strong>This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ... Show More
36m 11s
Aug 2024
EHA 2024 Recap: Optimizing the Relapsed/Refractory CLL Treatment Pathway
<p>How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.<br />   <br /> Credit available for this activity expires: 07/31/25<br /> Earn Credit / Learning Obje ... Show More
37m 22s
Oct 2022
Cardiacast: Treatment for Amyloidosis Including Evidence-Based Therapies, Pitfalls, and Advanced Heart Failure Management
In this episode Richard Cheng MD and Michelle Kittleson MD discuss treatment for amyloidosis, including evidence-based therapies, pitfalls, and advanced heart failure management. This podcast is part of the Cardiac Amyloidosis: Accelerating Diagnosis and Treatment grant initiativ ... Show More
18m 19s
Dec 2023
87: WAAW with SPIDS - Catching CRABs
In the second of three episodes, listen to Dr. Fatimah Alshahrani and Dr. Abdullah Almohaizeie discuss carbapenem-resistance Acinetobacter!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com 
33m 13s
Oct 2024
The role of urologists in the treatment of mPCa patients
<p>In this interview, medical oncologist Dr. Elena Castro (ES) and Dr. Gianluca Giannarini (IT) discuss the challenges of managing treatment-related toxicity and quality of life for PCa patients, particularly hormone-sensitive patients. <br/><br/><em>This activity is supported by ... Show More
9m 8s
Jul 2023
Episode 15: Applying CKD Interventions
Join host Dr. Peter Lin (Canadian Heart Research Centre, Canada) in conversation with Dr. Joel Topf (Oakland University, William Beaumont School of Medicine, USA) as they discuss how to combat CKD progression and the role of non-pharmacological vs pharmacological interventions. T ... Show More
15 m
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
Jun 2022
#342 Checkpoint Inhibitors: The power, and adverse effects, of immunotherapy (ACP 2022)
With great power comes great immunogenicity. Learn about the ins and outs of immunotherapy–its indications, its power, and its adverse effects–in this episode with Dr. Christian Cable, hematologist/oncologist and medical educator extraordinaire. We learn a riveting history of imm ... Show More
54m 36s